Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long term low risk stocks. As the DeepSeek craze ignites a sell-off in the tech ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug ...